Spectris said it had completed the acquisition of drug development group Concept Life Sciences from Equistone Partners Europe and company management for £163m. The deal would be funded from existing cash and bank facilities, the company said. Concept's pro-forma revenue in the year through December was £48.7m and pro-forma Ebitda was £9.3m. "The business has a history of delivering double-digit growth and we expect that to continue," Spectris said.
-24.00p (-0.87%)delayed 17:30PM